Search - tctmd.com

Displaying 61 - 80 of 97

Sort: Relevancy | Date

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Second Deep Dive into SYMPLICITY HTN-3: Novel Mechanistic Insights from the Trial

Presenter: David Kandzari

September 14, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation Therapy

September 13, 2014

News Conference News ESC 2014

SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year

Todd Neale

September 01, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Yael L. Maxwell

June 11, 2014

News Daily News

SYMPLICITY HTN-2: La Denervación Renal es Segura y Eficaz a los 3 Años

Yael L. Maxwell

June 11, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Conference News EuroPCR 2014

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Yael L. Maxwell

May 22, 2014

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

News Daily News

Renal Denervation Shows Promise in Patients Refractory to Stenting

L.A. McKeown

May 02, 2014

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

Global SYMPLICITY Registry Still Shows Positive Results for Renal Denervation

Yael L. Maxwell

March 30, 2014

News Conference News ACC 2014

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Yael L. Maxwell

March 29, 2014

News Industry News

Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint

January 08, 2014

Advertisement

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Second Deep Dive into SYMPLICITY HTN-3: Novel Mechanistic Insights from the Trial

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

Experts Debate Future of Renal Denervation Therapy

SYMPLICITY HTN-3: Renal Denervation Still Safe, Not Effective at 1 Year

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

SYMPLICITY HTN-2: La Denervación Renal es Segura y Eficaz a los 3 Años

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Renal Denervation Shows Promise in Patients Refractory to Stenting

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Global SYMPLICITY Registry Still Shows Positive Results for Renal Denervation

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content